Gracey Craig sold $85K of OMDA

Gracey Craig (Chief Accounting Officer) sold 4,167 shares of Omada Health, Inc. (OMDA) at an average of $20.50 ($20.00–$21.00) across 2 trades over 2026-06-26 to 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gracey Craig
Published Jun 30, 2026, 11:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 11:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMDA
Neutral
high confidence
Mentioned
$OMDA
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMDANeutralLow
01

Why it matters

The disclosure updates OMDA’s insider trading record but does not include any new company performance, guidance, or strategic information.

02

Market read

Traders may log the insider sale for sentiment/positioning, but it is unlikely to drive a fundamental repricing.

03

What to watch

The sale size is modest and the plan is pre-arranged; without additional context (e.g., other insiders selling/buying), the signal is weak.

Relevance 2/10Novelty 3/10Timing: Filed 2026-06-30 after-hours; reflects trades dated 2026-06-26 to 2026-06-29.

Background

The filing is an SEC Form 4 insider transaction for Omada Health, reported by Chief Accounting Officer Gracey Craig.

Company-level read

Ticker impact

$OMDANeutralHigh confidence
Context

Omada Health insider Gracey Craig (Chief Accounting Officer) sold about $85.4K of OMDA stock via an open-market sale under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

Form 4 shows a small, pre-arranged 10b5-1 sale (weighted avg ~$20.50) by an accounting officer, with no accompanying operational or guidance change.

Market effects

No clear read-across to the healthcare/telehealth sector from a single small 10b5-1 insider sale.

No material regional impact indicated.

No global implications indicated.

Counterpoint

Even 10b5-1 sales can coincide with internal views on near-term valuation, so traders may watch for follow-on insider activity.

Key entities

  • Omada Health, Inc.

    Issuer of the Form 4 insider sale disclosed on 2026-06-30.

  • Gracey Craig

    Chief Accounting Officer who sold 4,167 shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OMDAHigh

Omada Health Earnings Call Signals Strong Growth Ahead

Omada Health (OMDA) reported Q3 revenue of $91M, up 34% YoY, with GAAP net income of $7M vs. a loss last year. Adjusted EBITDA rose to $12M. Management raised 2026 revenue guidance to $344M-$346M and adjusted EBITDA to $32M-$34M, citing strong demand for diabetes and hypertension programs. The company expects Q4 seasonality and GLP-1 coverage uncertainty.

$OMDAMed

What Omada Health (OMDA) Said on Its Q3 Earnings Call

Omada Health (OMDA) expects Q4 revenue to decline due to seasonal factors, with adjusted EBITDA also moderating. The company ended Q3 with $243M in cash and no debt. CEO Sean Duffy will transition to executive chair in 2027, with Shao taking over as CEO. Omada's GLP-1 Care Track showed a 6% average weight loss at 12 weeks, according to peer-reviewed research.

$OMDAMedAI 8/10

Omada Health Inc (OMDA) (Q3 2026) Earnings Call Highlights: Record Revenue, Membership

Omada Health Inc (OMDA) reported record revenue and membership growth in Q3 2026. However, new enrollments are expected to decline in Q4 due to seasonality and tough comparisons. GLP-1 market dynamics and rising healthcare costs create uncertainty for 2027. Adjusted EBITDA is expected to moderate due to increased R&D and staffing. The company aims for 20%+ growth in 2027 through expanding covered lives, improving enrollment rates, and increasing engagement.